A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Inclusion Criteria: * Has either clinically definite or laboratory-supported definite relapsing forms of MS for at least 2 years * Patients with SPMS or RRMS have documented medical history of relapse in the past year or MRI-documented evidence of MS activity in the past year * Has had an inadequate response or intolerability to interferon and/or glatiramer acetate * Is able and willing to undergo Gd administration and repeat MRI testing Exclusion Criteria: * Has primary progressive MS (PPMS) * Any history of treatment with recombinant humanized monoclonal antibodies * Has received treatment with immunosuppressant medications or experimental agents within 3 months prior to the Baseline * A history of opportunistic infection or the presence of any active infection within 3 months prior to Baseline * Any history of congestive heart failure or currently has a pacemaker * Has a known or suspected hypersensitivity to sulfonamides or any of the components of the investigational drug * Has any medical history or psychiatric condition that would impact outcome or study participation * Has other clinically significant abnormality on physical, neurological, laboratory, or ECG examination as listed in the protocol during the Screening Phase